Clinical Trials Browser

Phase 1/2 × OTHER × Eflornithine × Clear all

NCT06219174 2026-03-06

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)

Phase 1/2 Suspended

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06465199 2026-03-02

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Phase 1/2 Recruiting

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT06892678 2025-05-11

DFMO

Phase 1/2 Recruiting

Osteosarcoma Recurrent